Madrigal Pharmaceuticals, Inc. (MDGL) quarterly income statement — complete revenue, gross profit & net income history
| Sales/Revenue | 311.34M | 321.08M | 287.27M | 212.8M | 137.25M | 103.32M | 62.17M | 14.64M | 0 | 0 | 0 | 0 |
| Revenue Growth % | 126.84% | 210.77% | 362.03% | 1353.76% | - | - | - | - | - | - | - | - |
| Cost of Goods Sold | 26.85M | 24.45M | 18.12M | 9.06M | 4.51M | 3.44M | 2.15M | 636K | 0 | 0 | 0 | 0 |
| COGS % of Revenue | 8.62% | 7.61% | 6.31% | 4.26% | 3.29% | 3.33% | 3.46% | 4.34% | - | - | - | - |
| Gross Profit | 284.49M | 296.63M | 269.15M | 203.74M | 132.74M | 99.88M | 60.02M | 14M | 0 | 0 | 0 | 0 |
| Gross Margin % | 91.38% | 92.39% | 93.69% | 95.74% | 96.71% | 96.67% | 96.54% | 95.66% | - | - | - | - |
| Gross Profit Growth % | 114.33% | 197.01% | 348.4% | 1355.06% | - | - | - | - | - | - | - | - |
| Operating Expenses | 377.21M | 356.24M | 383.12M | 250.94M | 212.05M | 166.87M | 176.33M | 176.54M | 152.04M | 117.18M | 98.53M | 86.45M |
| OpEx % of Revenue | 121.16% | 110.95% | 133.37% | 117.92% | 154.5% | 161.51% | 283.6% | 1206.03% | - | - | - | - |
| Selling, General & Admin | 268.52M | 239.98M | 209.12M | 196.86M | 167.88M | 141.22M | 107.58M | 105.45M | 80.8M | 46.54M | 27.58M | 17.84M |
| SG&A % of Revenue | 86.25% | 74.74% | 72.8% | 92.51% | 122.31% | 136.69% | 173.04% | 720.37% | - | - | - | - |
| Research & Development | 108.69M | 116.27M | 174M | 54.08M | 44.17M | 25.65M | 68.74M | 71.09M | 71.24M | 70.64M | 70.95M | 68.61M |
| R&D % of Revenue | 34.91% | 36.21% | 60.57% | 25.41% | 32.18% | 24.82% | 110.56% | 485.66% | - | - | - | - |
| Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -92.72M | -59.61M | -113.97M | -47.2M | -79.31M | -67M | -116.3M | -162.54M | -152.04M | -117.18M | -98.53M | -86.45M |
| Operating Margin % | -29.78% | -18.57% | -39.68% | -22.18% | -57.79% | -64.84% | -187.06% | -1110.38% | - | - | - | - |
| Operating Income Growth % | -16.91% | 11.03% | 2% | 70.96% | 47.83% | 42.82% | -18.03% | -88.01% | -94.08% | -37.37% | -22.54% | -23.02% |
| EBITDA | -92.72M | -59.22M | -113.62M | -46.83M | -78.93M | -66.63M | -116.01M | -162.27M | -151.87M | -117.03M | -98.4M | -86.32M |
| EBITDA Margin % | -29.78% | -18.44% | -39.55% | -22% | -57.51% | -64.49% | -186.58% | -1108.55% | - | - | - | - |
| EBITDA Growth % | -17.47% | 11.13% | 2.06% | 71.14% | 48.03% | 43.07% | -17.89% | -87.98% | -94.18% | -37.41% | -22.55% | -23.03% |
| D&A (Non-Cash Add-back) | 0 | 392K | 358K | 377K | 379K | 363K | 298K | 267K | 168K | 142K | 135K | 126K |
| EBIT | -92.72M | -50.28M | -106.74M | -39.02M | -69.94M | -55.92M | -103.28M | -148.31M | -143.7M | -108.22M | -95.24M | -82.9M |
| Net Interest Income | 0 | 1.16M | 2.86M | 4.96M | 6.07M | 7.58M | 9.34M | 10.57M | 4.5M | 4.98M | -206K | 650K |
| Interest Income | 8.24M | 9.46M | 10.31M | 8.23M | 9.37M | 11.08M | 13.02M | 14.22M | 8.33M | 8.95M | 3.3M | 3.55M |
| Interest Expense | -7.82M | 8.3M | 7.45M | 3.26M | 3.3M | 3.5M | 3.68M | 3.66M | 3.84M | 3.97M | 3.5M | 2.9M |
| Other Income/Expense | -1.67M | 1.03M | -215K | 4.92M | 6.07M | 7.58M | 9.34M | 10.57M | 4.5M | 4.98M | -206K | 650K |
| Pretax Income | -94.39M | -58.58M | -114.19M | -42.28M | -73.24M | -59.42M | -106.96M | -151.97M | -147.54M | -112.19M | -98.74M | -85.8M |
| Pretax Margin % | -30.32% | -18.24% | -39.75% | -19.87% | -53.36% | -57.51% | -172.04% | -1038.2% | - | - | - | - |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Income | -94.39M | -58.58M | -114.19M | -42.28M | -73.24M | -59.42M | -106.96M | -151.97M | -147.54M | -112.19M | -98.74M | -85.8M |
| Net Margin % | -30.32% | -18.24% | -39.75% | -19.87% | -53.36% | -57.51% | -172.04% | -1038.2% | - | - | - | - |
| Net Income Growth % | -28.88% | 1.42% | -6.76% | 72.18% | 50.36% | 47.04% | -8.33% | -77.12% | -91.87% | -30.6% | -21.61% | -21.31% |
| Net Income (Continuing) | -94.39M | -58.58M | -114.19M | -42.28M | -73.24M | -59.42M | -106.96M | -151.97M | -147.54M | -112.19M | -98.74M | -85.8M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -3.25 | -2.57 | -5.08 | -1.90 | -3.32 | -2.71 | -4.92 | -7.10 | -7.38 | -5.68 | -5.34 | -4.69 |
| EPS Growth % | 2.11% | 5.17% | -3.25% | 73.24% | 55.01% | 52.29% | 7.87% | -51.39% | -74.47% | -14.06% | -12.42% | -13.29% |
| EPS (Basic) | -3.25 | -2.57 | -5.08 | -1.90 | -3.32 | -2.71 | -4.92 | -7.10 | -7.38 | -5.68 | -5.34 | -4.69 |
| Diluted Shares Outstanding | 29.03M | 22.43M | 22.48M | 22.21M | 22.09M | 21.93M | 21.75M | 21.4M | 20M | 19.76M | 18.48M | 18.31M |
| Basic Shares Outstanding | 29.03M | 22.43M | 22.48M | 22.21M | 22.09M | 21.93M | 21.75M | 21.4M | 20M | 19.76M | 18.48M | 18.31M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - | - | - |